Tax Inversion

All articles by Tax Inversion

Five things for pharma marketers to know: Wednesday, December 20, 2017
Five things for pharma marketers to know: Wednesday, December 20, 2017
Virginia Lau
December 20, 2017
2:20 pm

Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease

Five things for pharma marketers to know: Wednesday, July 13, 2016
Five things for pharma marketers to know: Wednesday, July 13, 2016
Jaimy Lee
July 13, 2016
1:55 pm

Gilead reportedly avoiding paying billions in taxes; Merck plans to cut R Sage’s treatment for postpartum depression meets trial goal

Five things for pharma marketers to know: Thursday, July 30
Five things for pharma marketers to know: Thursday, July 30
July 30, 2015
3:10 pm

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Five things for pharma marketers to know: Monday, December 1
Five things for pharma marketers to know: Monday, December 1
David Vaczek
Deborah Weinstein
December 1, 2014
4:06 pm

GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir’s inhalable migraine medication.

AbbVie-free Shire could open new opportunities
AbbVie-free Shire could open new opportunities
Deborah Weinstein
October 16, 2014
7:50 pm

AbbVie’s board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

AbbVie reconsiders Shire
AbbVie reconsiders Shire
Deborah Weinstein
October 15, 2014
6:22 pm

AbbVie is thinking about modifying or walking away from its offer to buy Dublin’s Shire. A breakup would cost the Illinois company over $1.6 billion.

Cosmo moves to Ireland
Cosmo moves to Ireland
October 15, 2014
6:13 pm

Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.

New Ireland tax rule does not fluster pharma
New Ireland tax rule does not fluster pharma
October 14, 2014
5:47 pm

Ireland plans on closing off a tax advantage but pharma does not appear to flinch.

Five things for pharma marketers to know: Friday, October 3
Five things for pharma marketers to know: Friday, October 3
Deborah Weinstein
October 3, 2014
12:58 pm

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers’ attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Five things for Pharma Marketers to know: Monday, September 29
Five things for Pharma Marketers to know: Monday, September 29
Deborah Weinstein
September 29, 2014
12:57 pm

Inversion rules have Medtronic asking for a Covidien do-over, Roche’s Perjeta has “unprecedented success,” while AstraZeneca’s Iressa does not.

  • From Our Partners